|
Age, years, M (IQR)
|
66 (61–72)
|
69 (64–74)
|
2
|
0.681
|
67 (62–72)
|
67 (57–70)
|
2
|
0.981
|
|
Sex, n (%)
| | | |
0.469
| | | |
0.777
|
|
Women
|
41 (48%)
|
8 (38%)
|
2
| |
26 (55%)
|
8 (50%)
|
1
| |
|
Men
|
44 (52%)
|
13 (62%)
| | |
21 (45%)
|
8 (50%)
|
1
| |
|
Tumour origin, n (%)
| | | |
0.852
| | | |
0.487
|
|
Duodenum
| | | | |
12 (26%)
|
2 (13%)
| | |
|
Ampulla Intestinal type
| | | | |
35 (74%)
|
14 (87%)
|
2
| |
|
Ampulla Pancreatobiliary type
|
16 (19%)
|
3 (14%)
| | | | | | |
|
Distal bile duct
|
34 (40%)
|
10 (48%)
|
1
| | | | | |
|
Pancreas
|
35 (41%)
|
8 (38%)
|
1
| | | | | |
|
Tumour size, mm, M (IQR)
|
30 (25–35)
|
28 (21–30)
|
2
|
0.799
|
25 (15–40)
|
30 (24–40)
|
2
|
0.848
|
|
Differentiation grade, n (%)
| | | |
0.211
| | | |
0.148
|
|
Well-moderate
|
34 (40%)
|
5 (24%)
|
1
| |
26 (55%)
|
5 (31%)
|
1
| |
|
Poor
|
51 (60%)
|
16 (76%)
|
1
| |
21 (45%)
|
11 (69%)
|
1
| |
|
T-stage, n (%)
| | | |
1.000
| | | |
0.860
|
|
T1
|
2 (2%)
|
0
|
1
| |
4 (9%)
|
0
|
1
| |
|
T2
|
8 (9%)
|
2 (10%)
| | |
8 (17%)
|
3 (19%)
|
1
| |
|
T3
|
61 (72%)
|
16 (76%)
|
1
| |
18 (38%)
|
7 (44%)
| | |
|
T4
|
14 (16%)
|
3 (14%)
| | |
17 (36%)
|
6 (37%)
| | |
|
N-stage, n (%)
| | | |
0.421
| | | |
0.564
|
|
N0
|
25 (29%)
|
4 (19%)
|
2
| |
26 (55%)
|
7 (44%)
|
2
| |
|
N1-N2
|
60 (71%)
|
17 (81%)
| | |
21 (45%)
|
9 (56%)
| | |
|
Margins, n (%)
| | | |
1.000
| | | |
1.000
|
|
R0
|
5 (6%)
|
1 (5%)
|
1
| |
13 (28%)
|
4 (25%)
|
1
| |
|
R1-Rx
|
80 (94%)
|
20 (95%)
|
1
| |
34 (72%)
|
12 (75%)
|
1
| |
|
Perineural growth, n (%)
| | | |
0.232
| | | |
0.533
|
|
No
|
20 (24%)
|
2 (10%)
|
1
| |
34 (72%)
|
10 (62%)
|
1
| |
|
Yes
|
65 (76%)
|
19 (90%)
|
1
| |
13 (28%)
|
6 (38%)
|
1
| |
|
Invasion of lymphatic vessels, n (%)
| | | |
0.792
| | | |
0.081
|
|
No
|
25 (29%)
|
7 (33%)
|
1
| |
25 (53%)
|
4 (25%)
| | |
|
Yes
|
60 (71%)
|
14 (67%)
|
1
| |
22 (47%)
|
12 (75%)
|
2
| |
|
Invasion of blood vessels, n (%)
| | | |
0.070
| | | |
0.594
|
|
No
|
60 (71%)
|
10 (48%)
|
1
| |
44 (94%)
|
14 (87%)
|
2
| |
|
Yes
|
25 (29%)
|
11 (52%)
|
1
| |
3 (6%)
|
2 (13%)
| | |
|
Growth in peripancreatic fat, n (%)
| | | |
0.760
| | | |
0.545
|
|
No
|
18 (21%)
|
3 (14%)
|
2
| |
32 (68%)
|
9 (56%)
|
2
| |
|
Yes
|
67 (79%)
|
18 (86%)
| | |
15 (32%)
|
7 (44%)
| | |
|
SATB2, n (%)
| | | |
0.092
| | | |
0.422
|
|
Negative
|
84 (99%)
|
18 (90%)
|
2
| |
40 (89%)
|
13 (81%)
|
0
| |
|
Positive
|
1 (1%)
|
2 (10%)
|
0
| |
5 (11%)
|
3 (19%)
|
0
| |
|
Missing
|
0
|
1
|
0
| |
2
|
0
|
2
| |
|
Adjuvant chemotherapy, n (%)
| | | |
0.739
| | | |
0.301
|
|
No adjuvant
|
41 (48%)
|
9 (43%)
|
1
| |
35 (74%)
|
10 (63%)
|
2
| |
|
5FU-analogue
|
5 (6%)
|
3 (14%)
| | |
4 (9%)
|
1 (6%)
| | |
|
Gemcitabine
|
35 (41%)
|
9 (43%)
| | |
5 (11%)
|
2 (13%)
| | |
|
Gemcitabine + capecitabine
|
1 (1%)
|
0
|
1
| |
0
|
1 (6%)
| | |
|
Oxaliplatin +5-FU analogue
|
1 (1%)
|
0
| | |
3 (6%)
|
1 (6%)
| | |
|
Gemcitabine + oxaliplatin
|
2 (2%)
|
0
| | |
0
|
1 (6%)
| | |
|
Recurrence
| | | |
0.250
| | | |
0.658
|
|
No
|
16 (19%)
|
3 (14%)
|
1
| |
27 (57%)
|
7 (44%)
|
1
| |
|
Yes, local only
|
25 (29%)
|
3 (14%)
|
1
| |
3 (6%)
|
1 (6%)
| | |
|
Yes, non-local
|
44 (52%)
|
15 (71%)
| | |
17 (36%)
|
8 (50%)
|
1
| |
|
Included in survival analyses
| | | |
1.000
| | | |
1.000
|
|
Yes
|
84 (99%)
|
21 (100%)
|
0
| |
45 (96%)
|
16 (100%)
|
0
| |
|
No
|
1 (1%)
|
0
|
2
| |
2 (4%)
|
0
|
2
| |
